Replimune Group, Inc. (REPL) News
Filter REPL News Items
REPL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
REPL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest REPL News From Around the Web
Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company recently granted equity awards to 30 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregat |
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsWOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naïve metastatic uveal melanoma; and second-line recurrent or metastatic hepatocellular carcinoma (HCC). “On the heels of our BLA submission for RP1 and designation as breakthrough therapy |
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceWOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 |
Replimune Announces Pricing of Upsized Public OfferingBOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public offering price of $13.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 3,846,184 shares of its |
Replimune Announces Proposed Public OfferingWOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriter a 30-day option to purchase up to an addition |
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 ResultsU.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining by more than 350 points on Friday. The Dow traded up 0.82% to 44,228.50 while the NASDAQ rose 0.14% to 18,998.27. The S&P 500 also rose, gaining, 0.31% to ... |
Replimune Stock Rallies on BLA Filing for Melanoma Combo DrugREPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma. |
Replimune's stock surges 19% after-hours on FDA BLA submissionShares of Replimune Group Inc (NASDAQ:REPL) surged more than 19% in after-hours trading following the company's announcement of significant regulatory progress for its lead product candidate, RP1 (vusolimogene oderparepvec). The clinical-stage biotechnology firm has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration seeking accelerated approval for RP1, an oncolytic immunotherapy, in combination with nivolumab. “We view these updates as encouraging and supportive of regulatory submission of RP1 in combination with nivolumab for anti-PD-1-failed melanoma,” said analysts at Leerink in a note. |
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayWOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Acce |
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateCompleted Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma via the accelerated approval pathway before the end of the year IGNYTE-3 confirmatory trial of RP1(vusolimogene oderparepvec) in advanced melanoma underway with first patient enrolled in August Presented late-breaking abstracts at ESMO and SITC featuring the IGNYTE trial primary analysis showing clinical |